Absorption of pyrvinium pamoate
The DOI matches its Crossref record.
Abstract
Pyrvinium pamoate, tablets and suspension, was administered as single 350‐mg doses to 12 healthy male volunteers to determine whether there had been any systemic absorption. Six subjects received tablets and 6 received suspension on the first day; on day 8, subjects received the other dose form. Up to 4 days after administration there was no evidence of drug in blood and urine by spectroflorometric assay. Metabolic studies in rats showed minute quantities of drug in the liver and plasma but not of any metabolites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“Although pyrvinium also showed inhibitory ability in other Wnt/β-catenin signaling-driven tumor cell lines (SUM-149/SUM-159,(358) and A2278(359)), its bioavailability was low in tissues other than the intestine.(360) In addition, pyrvinium also stimulated CK1γ, leading to Wnt signaling suppression.”
BackgroundIdentification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675
“Although niclosamide has a pharmacokinetic flaw of low absorption, further development or drug formulation could enable an effective delivery of this drug to the target tissue (10).”
BackgroundGassen, N. C., Niemeyer, D., Muth, D., Corman, V. M., Martinelli, S., Gassen, A., Hafner, K., Papies, J., Mösbauer, K., Zellner, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13659-4 · Cited by 356
Esumi, H., Lu, J., Kurashima, Y., & Hanaoka, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03330.x · Cited by 127
De Cremer, K., Lanckacker, E., Cools, T. L., Bax, M., De Brucker, K., Cos, P., Cammue, B. P. A., & Thevissen, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04229-14 · Cited by 77
The novel role of pyrvinium in cancer therapy
Momtazi‐borojeni, A. A., Abdollahi, E., Ghasemi, F., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26006 · Cited by 75
Simm, C., Weerasinghe, H., Thomas, D. R., Harrison, P. F., Newton, H. J., Beilharz, T. H., & Traven, A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00100-22 · Cited by 38
“FDA-approved anthelmintic drug and is safe to use in human even at high dosage of 350 mg per tablet (37).”
BackgroundSchultz, C. W., McCarthy, G. A., Nerwal, T., Nevler, A., DuHadaway, J. B., McCoy, M. D., Jiang, W., Brown, S. Z., Goetz, A., Jain, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0652 · Cited by 34
Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells
Xu, F., Zhu, Y., Lu, Y., Yu, Z., Zhong, J., Li, Y., & Pan, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8006 · Cited by 26
Ponzini, F. M., Schultz, C. W., Leiby, B. E., Cannaday, S., Yeo, T., Posey, J., Bowne, W. B., Yeo, C., Brody, J. R., Lavu, H., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073839 · Cited by 15
“…humans that examined the safety and maximum tolerated dose (MTD) of PP showed that PP has no bioavailability at 5 mg/kg, after a single oral dose, 13 while another study showed different patient cohorts were able to tolerate PP at 15–25 mg/kg, oral, for 5 days, and 35 mg/kg, oral, for 3 days,…”
Background
Metadata
- Authors
- Smith, T. C., Kinkei, A. W., Gryczko, C. M., & Goulet, J. R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1976-06
- Volume
- 19
- Issue
- 6
- Pages
- 802-806
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2342039626
- Cited by
- 62
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.